Pfizer Inc. $PFE is PARK CIRCLE Co’s 10th Largest Position

PARK CIRCLE Co raised its holdings in Pfizer Inc. (NYSE:PFE) by 47.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 122,705 shares of the biopharmaceutical company’s stock after acquiring an additional 39,205 shares during the period. Pfizer accounts for about 2.6% of PARK CIRCLE Co’s holdings, making the stock its 10th biggest position. PARK CIRCLE Co’s holdings in Pfizer were worth $3,127,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. Koshinski Asset Management Inc. raised its stake in Pfizer by 33.5% during the second quarter. Koshinski Asset Management Inc. now owns 30,976 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 7,768 shares during the period. United Bank grew its stake in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the period. Finally, Signature Estate & Investment Advisors LLC increased its holdings in shares of Pfizer by 19.3% during the 2nd quarter. Signature Estate & Investment Advisors LLC now owns 22,976 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 3,722 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.4%

NYSE PFE opened at $27.58 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The business has a 50 day moving average price of $25.84 and a two-hundred day moving average price of $25.23. The stock has a market cap of $156.78 billion, a PE ratio of 20.28 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Morgan Stanley reduced their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, UBS Group began coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.00.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.